Treatment of invasive candidal infections: Systematic review and meta-analysis

Mayo Clinic Proceedings

Volumn 83, Issue 9, 2008, Pages 1011-1021

  Gafter Gvili, Anat ^a,b   Vidal, Liat ^a,b   Goldberg, Elad ^a,b   Leibovici, Leonard ^a,b   Paul, Mical ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; VORICONAZOLE;

CANDIDEMIA; CANDIDIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; META ANALYSIS; MORTALITY; NEPHROTOXICITY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 51349150675     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/83.9.1011     Document Type: Article

References (40)

1. Pappas PG. Invasive candidiasis. Infect Dis Clin North Am. 2006;20(3):485-506.
2. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007;20(1):133-163.
3. Pappas PG, Rex JH, Lee J, et al; NIAID Mycoses Study Group. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis. 2003 Sep 1;37(5):634-643. Epub 2003 Aug 14.
4. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis. 2005 Nov 1;41(9):1232-1239. Epub 2005 Sep 20.
5. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis. 2004 Jan 15;38(2):161-189. Epub 2003 Dec 19.
6. Higgins JPT, Green S. eds. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6. [updated September 2006]. In: The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley & Sons. http://www.cochrane.org/ resources/handbook/Handbook4.2.6Sep2006.pdf. Accessed July 22, 2008.
7. Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998;352(9128):609-613.
8. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560.
9. Colombo AL, Perfect J, DiNubile M, et al. Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis. 2003 Aug;22(8):470-474. Epub 2003 Jul 23.
10. DiNubile MJ, Hille D, Sable CA, Kartsonis NA. Invasive candidiasis in cancer patients: observations from a randomized clinical trial. J Infect. 2005;50(5):443-449.
11. Dranitsaris G, Phillips P, Rotstein C, et al. Economic analysis of fluconazole versus amphotericin B for the treatment of candidemia in nonneutropenic patients. Pharmacoeconomics. 1998;13(5, pt 1):509-518.
12. Fainstein V, Bodey GP, Elting L, Maksymiuk A, Keating M, McCredie KB. Amphotericin B or ketoconazole therapy of fungal infections in neutropenic cancer patients. Antimicrob Agents Chemother. 1987;31(1):11-15.
13. Krause DS, Reinhardt J, Vazquez JA, et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother. 2004;48(6):2021-2024.
14. Pachl J, Svoboda P, Jacobs F, et al; Mycograb Invasive Candidiasis Study Group. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis. 2006 May 15;42(10):1404-1413. Epub 2006 Apr 12.
15. Pelz RK, Hendrix CW, Swoboda SM, et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg. 2001;233(4):542-548.
16. Sorkine P, Nagar H, Weinbroum A, et al. Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: results of a prospective, randomized, controlled study in critically ill patients. Crit Care Med. 1996;24(8):1311-1315.
17. Wingard JR, Wood CA, Sullivan E, Berger ML, Gerth WC, Mansley EC. Caspofungin versus amphotericin B for candidemia: a pharmacoeconomic analysis. Clin Ther. 2005;27(6):960-969.
18. National Institutes of Health. A phase III, double-blind, randomized study to evaluate the safety and efficacy of isavuconazole versus caspofungin followed by voriconazole in the treatment of candidemia and other invasive Candida infections. http://clinicaltrials.gov/ct2/show/NCT00413218. Accessed July 23, 2008. NCT00413218.
19. Abele-Horn M, Kopp A, Sternberg U, et al. A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients. Infection. 1996;24(6):426-432.
20. Anaissie EJ, Darouiche RO, Abi-Said D, et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis. 1996;23(5):964-972.
21. Driessen M, Ellis JB, Cooper PA, et al. Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial. Pediatr Infect Dis J. 1996;15(12):1107-1112.
22. Kujath P, Lerch K, Kochendorfer P, Boos C. Comparative study of the efficacy of fluconazole versus amphotericin B/flucytosine in surgical patients with systemic mycoses. Infection. 1993;21(6):376-382.
23. Phillips P, Shafran S, Garber G, et al; Canadian Candidemia Study Group. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Eur J Clin Microbiol Infect Dis. 1997;16(5):337-345.
24. Rex JH, Bennett JE, Sugar AM, et al; Candidemia Study Group, National Institute of Allergy and Infectious Diseases Mycoses Study Group. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia.. N Engl J Med. 1994;331(20):1325-1330.
25. Mondal RK, Singhi SC, Chakrabarti A, Jayashree M. Randomized comparison between fluconazole and itraconazole for the treatment of candidemia in a pediatric intensive care unit: a preliminary study. Pediatr Crit Care Med. 2004;5(6):561-565.
26. Tuil O, Cohen Y. Itraconazole IV solution in the treatment of candidemia in non-neutropenic patients. Crit Care. 2003;7(suppl 2):P131. doi 10.1186/cc2020.
27. Rex JH, Pappas PG, Karchmer AW, et al; National Institute of Allergy and Infectious Diseases Mycoses Study Group. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis. 2003 May 15;36(10):1221-1228. Epub 2003 May 8.
28. Reboli AC, Rotstein C, Pappas PG, et al; Anidulafungin Study Group. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007;356(24):2472-2482.
29. Mora-Duarte J, Betts R, Rotstein C, et al; Caspofungin Invasive Candidiasis Study Group. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347(25):2020-2029.
30. Arrieta A, Telles Filho F, Berezin E, Freire A, Diekmann-Berndt H. A randomized, double-blind trial comparing micafungin (MCFG) and liposomal amphotericin B (L-AMB) in pediatric patients with invasive candidiasis (IC). In: Program and Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA; September 27-30, 2006. Abstract M-1308b.
31. Kuse ER, Chetchotisakd P, da Cunha CA, et al; Micafungin Invasive Candidiasis Working Group. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet. 2007;369(9572):1519-1527.
32. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007 Oct 1;45(7):883-893. Epub 2007 Aug 29.
33. Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet. 2005;366(9495):1435-1442.
34. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818-829.
35. Bennett JE. Echinocandins for candidemia in adults without neutropenia. N Engl J Med. 2006;355(11):1154-1159.
36. Warn PA, Sharp A, Morrissey G, Denning DW. In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis. J Antimicrob Chemother. 2002;50(6):1071-1074.
37. Moudgal V, Little T, Boikov D, Vazquez JA. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother. 2005;49(2):767-769.
38. Robenshtok E, Gafter-Gvili A, Goldberg E, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol. 2007 Dec 1;25(34):5471-5489. Epub 2007 Oct 1.
39. Cruciani M, de Lalla F, Mengoli C. Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis. Intensive Care Med. 2005 Nov;31(11):1479-1487. Epub 2005 Sep 20.
40. Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. J Antimicrob Chemother. 2006 Apr;57(4):628-638. Epub 2006 Feb 3.